Author | Elisabetta Landucci, MD

Articles

New Combinations With Epirubicin in Advanced Breast Cancer

May 01, 2001

ByPierfranco Conte, MD|Alessandra Gennari, MD|Elisabetta Landucci, MD|Valentina Guarneri, MD|Sara Donati, MD|Barbara Salvadori, MD|Carmelo Bengala, MD

Several trials have shown that anthracyclines and taxanes can be combined to achieve response rates ranging from 70% to 90%, with complete responses ranging from 19% to 41%. In an attempt to increase the activity while

Epirubicin/Taxane Combinations in Breast Cancer: Experience From Several Italian Trials

May 01, 2001

ByPierfranco Conte, MD|Alessandra Gennari, MD|Valentina Guarneri, MD|Elisabetta Landucci, MD|Sara Donati, MD|Barbara Salvadori, MD|Carmelo Bengala, MD|Editta Baldini, MD

Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing